UNIQURE N.V. news, videos and press releases - Page 5
For more news please use our advanced search feature.
UNIQURE N.V. - More news...
UNIQURE N.V. - More news...
- uniQure to Participate in Multiple Upcoming Investor Conferences in April
- uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B
- uniQure to Participate in Multiple Upcoming Industry Conferences in March
- uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters
- uniQure Announces 2019 Financial Results and Highlights Recent Company Progress
- uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference
- uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
- uniQure to Participate in Multiple Upcoming Industry Conferences in February
- uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach
- uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
- uniQure to Participate in Multiple Upcoming Industry Conferences in December
- uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting
- uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy
- uniQure to Participate in Multiple Upcoming Industry Conferences in November
- uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
- uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
- uniQure to Participate in Multiple Upcoming Industry Conferences in October
- uniQure Announces Pricing of its Public Offering
- uniQure to Participate in Multiple Upcoming Industry Conferences in September
- uniQure Announces Leadership Promotions and Executive Transition
- uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress
- uniQure to Participate in Multiple Upcoming Industry Conferences
- uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
- uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
- uniQure to Participate in Multiple Upcoming Industry Conferences
- uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
- uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
- uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
- uniQure to Participate in Multiple Upcoming Industry Conferences
- uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress
